John Leonard Biography and Net Worth

After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as chief scientific officer and senior vice president of R&D at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. He became Intellia’s president and chief executive officer in January 2018.

John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the global head of pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His groundbreaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research.

In addition to serving on the board of directors of Intellia, John serves on the board of directors of IQVIA (NYSE: IQV) and IFM Therapeutics. He received his M.D. from Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine, followed by a fellowship at the National Institutes of Health.

What is John M. Leonard's net worth?: The estimated net worth of John M. Leonard is at least $10.31 million as of January 3rd, 2024. Dr. Leonard owns 846,486 shares of Intellia Therapeutics stock worth more than $10,310,199 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Leonard may own. Additionally, Dr. Leonard receives a salary of $1,060,000.00 as CEO at Intellia Therapeutics. Learn More about John M. Leonard's net worth.
How old is John M. Leonard?: Dr. Leonard is currently 67 years old. There are 8 older executives and no younger executives at Intellia Therapeutics. The oldest executive at Intellia Therapeutics is Dr. David Lebwohl M.D., Executive VP & Chief Medical Officer, who is 69 years old. Learn More on John M. Leonard's age.
What is John M. Leonard's salary?: As the CEO of Intellia Therapeutics, Inc., Dr. Leonard earns $1,060,000.00 per year. The highest earning executive at Intellia Therapeutics is Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board, who commands a salary of $1,380,000.00 per year. Learn More on John M. Leonard's salary.
How do I contact John M. Leonard?: The corporate mailing address for Dr. Leonard and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on John M. Leonard's contact information.
Has John M. Leonard been buying or selling shares of Intellia Therapeutics?: John M. Leonard has not been actively trading shares of Intellia Therapeutics during the last ninety days. Learn More on John M. Leonard's trading history.
Who are Intellia Therapeutics' active insiders?: Intellia Therapeutics' insider roster includes Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.
Are insiders buying or selling shares of Intellia Therapeutics?: In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company. Learn More about insider trades at Intellia Therapeutics.
Information on this page was last updated on 10/2/2024.

John M. Leonard Insider Trading History at Intellia Therapeutics

John M. Leonard Buying and Selling Activity at Intellia Therapeutics

Intellia Therapeutics Company Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $12.18

$11.85

$12.45

50 Day Range

MA: $15.59

$12.02

$21.08

2 Week Range

Now: $12.18

$11.79

$34.87

Volume

3,676,135 shs

Average Volume

1,784,817 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

John Leonard Biography and Net Worth

What is John M. Leonard's net worth?

How old is John M. Leonard?

What is John M. Leonard's salary?

How do I contact John M. Leonard?

Has John M. Leonard been buying or selling shares of Intellia Therapeutics?

Who are Intellia Therapeutics' active insiders?

Are insiders buying or selling shares of Intellia Therapeutics?